Ipsos Healthcare has extended its syndicated Psoriasis and IBD Therapy Monitors into China, where it will also re-launch its Lupus Therapy Monitor.
The new Chinese autoimmune studies, part of Ipsos’ syndicated Global Therapy Monitor portfolio, will incorporate real patient record data with doctors’ perceptions to analyse the current market landscape, market shares, reasons behind treatment trends and potential impact of products in development. They will complement Ipsos Healthcare’s existing real world evidence offer in China, which spans oncology, diabetes, cardiovascular, respiratory and virology diseases.
The new monitors come in response to local and multinational companies’ increasing focus on understanding the rapidly evolving treatment landscape across multiple autoimmune diseases in China. Specifically, they will offer subscribers an in-depth analysis of the various factors shaping treatment choice in these increasingly complex indications, including drivers for and barriers to the uptake of biologics.
Pieter De Richter, Regional Head of APAC Syndicated at Ipsos Healthcare, comments, “The uptake of biologics for the treatment of autoimmune diseases has been slower in China than in established markets such as the US and Europe. However, the large number of patients suffering from these often debilitating conditions, linked to continuous improvements in reimbursement cover and access, present a huge opportunity for pharma companies offering effective and well-tolerated therapies. Furthermore, the dynamic between innovator compounds and biosimilars is particularly important to understand in the Chinese market, given the high penetration of local biosimilar brands and the importance of affordability.”
Web : https://www.ipsos.com